Who we are

At a glance

Founded in 1999, genOway is a global biotechnology company offering preclinical models and solutions to leading bio-pharmaceutical companies and academic institutions for ultimate predictability.

Based on its core business and leading expertise in custom-designed preclinical models of high predictability, the company has developed its own catalog of translational models with a primary focus on immuno-oncology and immunotherapy.

The company aims at providing unmatched preclinical solutions that predict the success of a molecule in order to accelerate next-generation drugs to patients.

The current genOway management committee is composed of six members: Alexandre Fraichard, Benjamin Bruneau, Cyrielle Chabrier, Florent Pons, Yacine Cherifi and Kader Thiam.

‍

‍

Headquartered in Lyon, France, genOway counts more than 140 employees* spanning 17 nationalities, and serves leading life sciences companies and academic institutions in 28 countries on five continents.

Mission and vision

genOway's mission is to design and create genetically modified mice, rats, and cell lines of higher physiological relevance in order to better mimic that of humans and improve the predictability of preclinical research for the benefit of human health.

Our vision is to provide Ultimate Predictability in preclinical research thanks to both an unrivaled intimate collaboration with our clients and strong scientific expertise in designing genetically modified models and understanding biological physiology.

‍

Value proposition

Our broad technologic and scientific platform enables the design and creation of models for research, target validation, drug screening, efficacy, and non-regulatory safety testing.

The value of the scientific data obtained from these models is proportional to the quality of the model design. Thus, the generation of the right research or preclinical model requires a thorough analysis of the target gene biology paired with a clear assessment of the specificities of each customer project.

genOway’s hallmark is indeed the scientific input provided to understand its customers’ scientific questions and to offer the right solution to answer them.

We invest heavily in our consulting activity, especially to create new models, but also to contribute to the experimental design and analyze the data with the ultimate objective to maximize the predictability of the data produced.

When creating a new model for a client, genOway provides an integrated service consisting of performing the first phenotyping studies, evaluating the model's main physiological characteristics once the first animals are available, and handling line amplification. This provides clients with cohorts ready for experimentation and enables them to focus on their specific in vivo or in vitro studies.

‍

Largest technology platform

genOway applies all the current technologies, including homologous recombination, nuclease-based gene editing,  internal ribosome entry site (IRES), recombinase-mediated cassette exchange (RMCE), FLEx and TET-On/Off to generate all types of models such as Knockouts, conditional Knockouts with or without deletion monitoring, Knockins (overexpressions in endogenous or permissive loci), point mutations, humanizations, and inducible models.

‍

Unique intellectual property portfolio

genOway is the only provider that can guarantee your freedom to operate on all the models we develop. We have built a unique license portfolio for all technologies used, including exclusive licenses, which we are allowed to sublicense.

Furthermore, our customers retain ownership of the deliverables and can patent the model developed. genOway has no claim on the results generated by using the models we provide you.‍

‍

Highly qualified scientific teams

Most project managers, business developers and consultants have obtained a PhD in life sciences.

This guarantees both a perfect understanding of the preclinical expectations of the customer and the strengths and limitations of our solutions. We are proud to possess a strong knowledge of the limitations of our solutions, so as not to jeopardize the predictability of customers’ data and to efficiently develop the next generations of predictive solutions.

‍

Innovations

Scientists work at top-notch scientific aspects of their particular research fields. To satisfy our customers' expectations, we must translate their projects into the most optimally adapted and physiologically relevant tools.

That implies keeping pace with science and creating an environment that encourages innovative thinking.

Our technology-driven R&D team continually searches and tests new ideas, applications, methods and inventions with the goal to evolve our production lines and translate them into a service that creates value for our customers.

This innovation is increasingly performed in consortium and partnerships with our key customers.

genOway's innovative thinking goes further, and spreads throughout the whole company, continuously evolving customer care, LEAN management, and software solutions, to mention just a few.

‍

‍Cultural values

The values of genOway are: Passion for Excellence, Agility, Collaboration, Inclusion, and Sustainability.

‍

*Equality Index Men/Women: The global ratio for the 2023 exercise is 94/100.

*Index Egalité Hommes/Femmes: La note globale obtenu au titre de l’exercise 2023 est de 94/100.

‍